Structure-guided discovery of small-molecule ICOS-ICOSL antagonists that remodel intratumoral immunity and enhance anti-PD‑1 therapy in osteosarcoma.
The inducible T‑cell co‑stimulator (ICOS)-ICOS ligand (ICOSL) axis shapes effector versus regulatory T‑cell programs in tumors, yet small‑molecule disruption of this protein-protein interaction remains underexplored. We used the ICOS-ICOSL complex to define an interfacial hotspot and applied DrugCLIP to screen approxim...